Meeting
2013 ASCO Annual Meeting
A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
Authors
Kari Braun Wisinski
University of Wisconsin Carbone Cancer Center, Madison, WI
Kari Braun Wisinski , Amye Tevaarwerk , Maria Bell , Mark E. Burkard , Jens C. Eickhoff , George Wilding , Noelle K. LoConte , Anne M. Traynor , Tien Hoang , Jennifer Heideman , Jill Kolesar , Glenn Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
PI3-Akt-mTOR Pathway
Clinical Trial Registration Number
NCT01245205
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2607)
DOI
10.1200/jco.2013.31.15_suppl.2607
Abstract #
2607
Poster Bd #
10C
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.
First Author: M. Simonelli
Poster
2011 ASCO Annual Meeting
A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.
First Author: H. S. Han
Poster
2017 ASCO Annual Meeting
Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (Pts) with advanced solid tumors.
First Author: Ben Tran
Poster
2016 ASCO Annual Meeting
Phase I study of mTORC1/2 inhibitor BI 860585 as single agent or with exemestane or paclitaxel in patients with advanced solid tumors.
First Author: Filippo G. De Braud